In QuotedData’s morning briefing 15 October 2024: Bellevue Healthcare (BBH) says that redemption requests were received for the 22 November 2024 redemption point for 163,834,887 shares, representing 36.34% of the company’s issued share capital. Given the size of the proposed redemption, the board is proposing to create a redemption pool (carving off a slice of […]
The European Smaller Companies Trust has published results covering the 12 months ended 30 June 2024. The NAV total return of 12.0% was 1.9% ahead of the benchmark MSCI Europe ex UK Small Cap Index. The share price total return was 19.5%, reflecting a narrowing of the discount. The company repurchased a total of 6.4m […]
With the deal approved by both sets of shareholders, Witan’s investors got 0.224615 of a new Alliance Witan share for every Witan share that they held (based on formula asset values of 1274.592460 pence for Alliance Trust and 286.293752 pence for Witan). Willis Towers Watson has appointed Jennison Associates as an additional stock picker for […]
In QuotedData’s morning briefing 10 October 2024: As flagged yesterday, UIL (UTL) has entered into a sale and purchase agreement with General Provincial Life Pension Fund to acquire all of its stake (187,572,396 ordinary shares) in Zeta, following which UIL will own 95.03% of Zeta’s share capital. Based on Zeta’s NAV as at 8 October […]
Fidelity Emerging Markets has published results covering the year ended 30 June 2024 and they are good. After a difficult year in 2022, when the trust was hit hard by Russia’s invasion of Ukraine, and then a period of consolidation in 2023, for the latest year the trust reported a NAV total return of +18.7% […]
UIL has published results for the 12 months ended 30 June 2024. Highlights are: Net asset value total return of -15.3% (2023: -20.6%) Share price total return of -24.8% (2023: -18.5%) Revenue earnings per ordinary share of 10.15p (2023: 6.68p) Dividends per ordinary share of 8.00p (2023: 8.00p) Discount widened to 36.9% (2023: 27.5%) Gearing […]
Syncona has invested a further £19.9m in Purespring Therapeutics as part of an £80m oversubscribed Series B financing for that company. Syncona formed part of a leading Series B syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient Capital. Syncona founded Purespring in 2020 as one of the first adeno-associated virus […]
In QuotedData’s morning briefing 9 October 2024: RIT Capital Partners (RCP) has a new independent non-executive director and member of the Audit and Risk Committee, Helena Coles. Helena has extensive international experience and spent most of her career as a portfolio manager. She also brings valuable perspectives from asset owners and a UK regulator. She […]
The manager of RTW Biotech Opportunities has led a $400m Series A financing round for a new portfolio company, Kailera Therapeutics. The announcement does not disclose how much of that came from the listed fund. RTW Investments co-led the Series A with Atlas Venture and Bain Capital Life Sciences, with participation from Lyra Capital. The […]
Syncona has committed £63.5m in a Series B financing of Resolution Therapeutics, a company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. Syncona has invested an initial tranche of £22.0m, with investment of the full Series B commitment dependent upon the completion of key milestones. Alongside […]
